Explore

Therapeutic Areas Cell & Gene Therapy Designations Emerging Targets Companies

Dashboards Insights Briefs Pricing

Login

Back to EXELIXIS

EXELIXIS Pipeline

Clinical trials and expected approvals

Pro Feature

Get full access to pipeline analysis, trial details, and approval forecasts.

Already a Pro member? Login

-

Active Trials

-

Phase 3

-

Phase 2

-

Phase 1

-

Results Pending

📊

Pipeline Summary

Expected Approvals

FDA Decision 1 upcoming PDUFA date

Zanzalintinib (XL-092) + atezolizumab Pretreated metastatic colorectal cancer (mCRC) NDA

Dec 3, 2026 145 days Calendar →

Clinical Trials

Loading...

Therapeutic Areas

Oncology
Immunology
Cardiovascular
CNS
Metabolic
Infectious Disease
Respiratory
All areas →

Drug Targets

PD-1
TNF
ERBB2 / HER2
GLP-1R
VEGFA
EGFR
BTK
All targets →

Companies

Pfizer
Merck
AstraZeneca
Eli Lilly
Novo Nordisk
Bristol-Myers Squibb
Roche
All companies →

Explore

FDA Approvals
FDA Designations
Drug Database
Drug Targets
Biomarkers
Indications
Cell & Gene Therapy
Emerging Drugs
Conferences
Glossary
About

Data: FDA Drugs@FDA, ClinicalTrials.gov

Indication mapping uses a manual taxonomy — see methodology and coverage there.

What we're building Found an error? Let us know